Litcius/Paper detail

Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis

Stephen D. Smith, Paolo Lopedote, Yazeed Samara, Matthew Mei, Alex F. Herrera, Allison Winter, Brian T. Hill, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Caron A. Jacobson, Austin I. Kim, Paolo F. Caimi, Filippo Milano, Ajay K. Gopal

2020Clinical Lymphoma Myeloma & Leukemia25 citationsDOI

Topics & Concepts

MedicineRefractory (planetary science)Internal medicineBendamustineDiscontinuationRituximabSalvage therapyLymphomaGastroenterologyClinical trialNeutropeniaOncologySurgeryToxicityChemotherapyAstrobiologyPhysicsLymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders researchHER2/EGFR in Cancer Research
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis | Litcius